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Sunuuary In order to test whether circumvention of clinical resistance can be obtained in common solid
tumours by targeting different drug resistance mechanisms, a phase I chnical and immunological study was
designed. The purpose of the study was to determine the dose of cyclosporin A (CsA), in combination with
doxorubicin (DOX) and ifosfamide (IFX), needed to achieve steady-state whole-blood levels of 2000 ng ml-'
and the associated toxicity of this combination. Treatment consisted of CsA 5 mg kg-' as a 2 h loading
infusion, followed by a CsA 3 day continuous infusion (c.i.) (days 1 - 3) at doses that were escalated from 10
to 18 mg kg-' day-'. Chemotherapy consisted of DOX 55 mg m-2 by i.v. 24 h c.i. (day 2) and IFX 2 g m-'
i.v. over I h on days 1 and 3. Treatments were repeated every 4 weeks. Eighteen patients with previously
treated resistant solid tumours received 39 cycles. Mean steady-state CsA levels ) 2000 ng ml-' were reached
at 5 mg kg-' loading dose followed by a 3 day c.i. of 16mg kg-' day-' or greater. Haematological toxicity
was greater than expected for the same chemotherapy alone. One patient died of intracranial haemorrhage due
to severe thrombopenia. Other observed toxicities were: asymptomatic hyperbilirubinaemia (46% cycles), mild
nephrotoxicity (20% cycles), hypomagnesaemia (72% cycles), mild increase in body weight (100% cycles),
hypertension (15% cycles) and headache (15% cycles). Overall the toxicity was acceptable and manageable.
No alterations in absolute lymphocyte number, the lymphocyte subsets studied (CD3, CD4. CD8, CD19) or
CD4 CD8 ratio were observed in patients receiving more than one treatment cycle, although there were
significant and non-uniform variations in the values of the different lymphocyte subsets studied when pre- and
post-treatment values were compared. There was also a significant increase in the CD4XCD8 ratio. Tumour
regressions were observed in two patients (epidermoid carcinoma of the cervix and Ewing's sarcoma). The CsA
dose recommended for phase II trials is a 5 mg kg-' loading dose followed by a 3-day c.i. of 16 mg kg-' day-'
simultaneously with DOX and IFX at the doses administered in this study.
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The expression of the mdrl gene is a well-known mechanism
of multidrug resistance in vitro. The product of this gene,
P-glycoprotein (P-gp), is present in the membrane of cells of
many cancers and normal human tissues (Goldstein et al.,
1989; Pastan and Gottesman, 1991), and belongs to the
ATP-binding cassette superfamily of protein transporters. P-gp
removes cytotoxins belonging to the multidrug resistance
(MDR) phenotype from the cell membrane and from the
cytoplasm of the exposed cell. The drugs sharing the MDR
mechanism are derivatives of natural products and include
epipodophyllotoxins, anthracycines, vinca alkaloids, taxol,
actinomycin D and others.
The role of P-gp in clinical resistance has not been clearly
established, although it seems that the expression of P-gp
influences the response to therapy of certain tumours such as
acute leukaemias, neuroblastomas and paediatric sarcomas
(Chan et al., 1990, 1991; Marie et al., 1991; Pirker et al.,
1991; Campos et al., 1992).
Certain drugs are known to reverse MDR in vitro. One of
the most powerful non-cytotoxic agents effective in blocking
the function of P-gp is the immunosuppressive drug cyclos-
porn A (CsA). CsA is a substrate of P-gp and can com-
petitively inhibit this membrane protein at clinically attain-
able doses. Concentrations of 1000-2000ngml-' CsA are
needed to reverse MDR in vitro (Twentyman et al., 1987). At
these doses CsA can also suppress the induction of the DNA
repair genes (Kashami-Sabet et al., 1990) and may potentiate
the cytotoxicity of antineoplastic agents in human tumour
cells not expressing P-gp (Larsson and Mygren, 1990).
Among actively used antineoplastic agents doxorubicin
(DOX) belongs to the classical MDR phenotype whilst ifos-
famide (IFX) does not and the latter is not cross-resistant
with DOX. Ifosfamide causes glutathione depletion in vitro
and in vivo (Lind et al., 1989). It has also been reported that
the cytotoxicity of DOX is enhanced following depletion of
glutathione (GSH) levels (Lee et al., 1988). Thus it is possible
that simultaneous administration of IFX and DOX may
circumvent DOX resistance. We therefore started a phase I
study in order to test whether the combination of IFX and
DOX can be safely administered with CsA in patients with
resistant solid tumours.
Patients, material and methods
Patients with histologically proven measurable metastatic
cancer (excluding colon, renal, suprarenal, pancreatic and
hepatic carcinomas) were eligible for this study, provided
they met the following selection criteria: Karnofsky perfor-
mance status of 50% or more; age between 18 and 70 years;
adequate renal function (creatinine clearance> 60 ml min'
and creatinine< 1.4 mg%), hepatic function (bilirubin <
1.4 mg% and transaminases within normal limits) and bone
marrow function (leucocytes ) 3 000mm-3 and platelets)
75000 mm-3); ECG without significant abnormalities and
left ventricular ejection fraction (LVEF) > 45% as measured
by echocardiography or radionucide cardioangiography; and
finally, documented evidence of progressive disease 4 weeks
or more after the last chemotherapy or radiotherapy treat-
ment. No other simultaneous anti-tumour treatments were
allowed. Most patients were clinically resistant to previous
DOX-based chemotherapy at the time of entering this study.
Since clinical drug resistance may be intrinsic or acquired, we
defined intrinsic resistance as lack of response to prior drug
treatments and acquired resistance as an initial response to
combination chemotherapy followed by progressive disease
while on treatment. Our experimental protocol was initiated
within 2 months of cessation of previous treatment which
had failed (as evident from progression of disease). Ethical
approval was obtained from the Institutional Ethical and the
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Spanish Health Department Research Protocol Committee.
All patients gave wrtten informed consent.
Before each treatment cycle, patients were assessed by a
complete history and physical examination, full blood cell
counts, serum biochemistry, creatinine clearance, liver fimc-
tion tests (SGOTSGPT, F-(GT alkaline phosphatase, LDH
and bilirubin), tumour measurements and immunological
fimction studies, including the determination of the lym-
phocyte subpopulations (CD3, CD4, CD8 and CDl9) and
the lymphocyte transformation index (LTI) with phyto-
haemagglutinin (PHA) stimulation. Lymphocyte subpopula-
tions were asd by flow cytometry, using the following
monoclonal antibodies: B4 (CD19) FITC, CD3 RD1, T4(CD4) FHTC and T8 (CD8) RDI (all from Coulter, Hialah,
FL, USA). Cells were marked using a Q-Prep Epics
Immunology Workstation (Coulter), according to the manu-
facturer's instructions. Samples were analysed on an EPICS
Profile-H (Coulter). All the immunological studies were
repeated approximately 12 h after finishing the treatment
cycle in order not to miss the lowest values on later days.
The coincidence with the nadir of chemotherapy aplasia
might hamper a proper evaluation if some of these values
become undetectable. Creatinine, bilirubin and magnesium
were measured daily during treatment. Full blood cell counts,
serum biochemistry, creatinine, magnesum, bilirubin and
liver function tests, were performed on the fourth and 14th
days after chemotherapy.
Treatment programme
An intravenous loading dose of CsA (Sandimmune; Sandoz,
East Hanover, NJ, USA), 5mg kg-', was given over 2 h,
followed by an intravenous (i.v.) continuous infusion (c.i.)
for 3 days (days 1-3) using a dose escalation design.
Simultaneously with the CsA c.i. and through a different
separate peripheral venous access IFX, 2 gm2, was admin-isterd i.v. over 1 h on days 1 and 3 (with the uroprotector
mesna). DOX, 55 mg m-2, 24 h i.v. c.i. was adminied on
day 2. Treatments were repeated every 4 weeks, provided the
WBC count was > 3000 mm 3 and the platelets>75000
mm-3, until tumour progression was documented. In addi-
tion, treatment was terminated when the total cumulative
dose of DOX reached 550 mg m-2. The maXimal total
cumulative dose of DOX allowed before starting the experi-
mental protocol was 300 mg m2. Concentrations of CsA in
whole blood were monitored at the end of the loading
infusion and at 12, 24, 36, 48 and 60 h after the beginning of
the continuous infusion. Blood levels were taken from a
peripheral vein far from the CsA infusion site. CsA was
measured using a fluorescence polarisation immunoassay,
with high specifiity for the parent compound and cross-
reactivity with the AMI and AM9 metabolites of 10.2% and
12% respectively (Abbot Diagnostics, Abbot Park, IL, USA).
Dose escalations for the CsA ci. are summarised in Table I.
The starting CsA infision dose of l0mgkg-' day-', was
seected because preliminary reports ed that steady-
state levels of CsA close to 1000 ng ml-' could be safely
achieved with this dose (Sonneveld et al., 1992; Erichman et
al., 1993). For this reason only two patients were started at
this dose level and a greater number of patients was included
in higher dose escalation levels. This design was to ensure
that all patients receive a CsA dose which modulates resis-
tance in vitro.
Our aim was to increase the CsA dose until a targeted
steady-state level of 2000 ng ml-' CsA was achieved or the
Tae I Cycknporin A continuous infusion dose escalations
Daselel CsA c.i. dose Patients Cycles
I 1Omgkg-' day-' 2 3
2 12mgkg-' day-' 3 9
3 14mgkg' day-' 6 15
4 16mgkg-' day-' 4 8
5 18mgkg-' day-' 3 4
maximum tolerated dose (MTD) was reached. Dose escala-
tions were permitted between different patients but not in the
same patient. The single exception was a patient who
obtained low steady-state levels of CsA in comparison with
the other patients included at the same dose escalation level
and showed improvement of her disease after the first treat-
ment cycle. We planned to increase the dose after a minimum
of three patients had been treated without showing grade III
or IV toxicities (excluding myelosuppression, nausea or
vomiting). Icrease in bilirubinaemia during CsA therapy did
not preclude dose escalations. If one patient showed grade III
or IV toxicity at a given dose level, three additional patients
were added at that level. Then if only one patient among the
six had a grade III or IV toxicity, dose escalation was
allowed to continue. The MTD of CsA was considered to be
the dose level at which two of six patients had a grade m or
IV toxicity. If two out of three or three out of six patients
presented a grade m or IV toxicity, the MTD was defined as
the previous lower level.
Evaluation of response and toxicity: dose modifications
World Health Organization (WHO) criteria were used to
evaluate response and toxicity of this protocol (WHO, 1979).
CsA infusion was interrupted if serum creatne rose to
more than 50% of baseline during treatment. Patients were
removed from the study when creatinine clarance was less
than 40 ml min-' or creatinine value was more than
2 mg dl-' at the beginning of a new treatment cycle. DOX
and IFX doses were reduced by 25% in subsequent cycles if
patients developed grade IV leucopenia (<1000mm -3) and/
or grade IV thrombopenia (<25 000 mm 3) in the nadir, or
neutropenic fever appeared. DOX dose was reduced by 25%
in subsequent cycles if patients developed grade MII or IV
mucositis.
Statistical methods
To compare absolute and relative values of lymphocyte sub-
populations CD3, CD4, CD8, CD19, CD4/CD8 and the LTI
where data was available, we used the Wilcoxon matched-
pairs test This analysis was performed using the statistical
package SPSS/PC + version 4.00 (SPSS, Chicago, IL, USA).
The above parameters obtained before each cycle of treat-
ment were compared with those obtained after each cycle.
Also, in patients who rcived more than one cycle of treat-
ment, the vahls drawn before the beginning of the last ccle
were compared with those obtaied before the first treat-
ment.
Res
The characteristics of the 18 patients treated in this study are
shown in Table H. Thirteen patients (72%) had reeived
DOX as part of their previous chemotherapy, seven (39%)
reived mitoxantrone (DHAD), five (28%) both drugs, and
four (22%) etoposide.
Twelve patients (66.6%) had been treated with one
chemotherapy programme before entering this protocol, three
patients (16.6%) with two different chemotherapy progam
mes and three patets (16.6%) with more than two pro-
grammes. Ten patients had had radiotherapy.
The most common tumour tYPes were breast cancer (five
patiets) and soft tissue sarcoma (five patients). There was
one patient each with epdemoid carcinoma of the cervix,
multiple myeloma, gastric adenoarcinoma, and gnglio-
neuroblastoma. Seven patients - three Complete response(CR) and four partial response (PR) - to previous
treatment, while 11 patients had never presented an objective
sso n - seven stable disease (SD) and four progre
dies (PD).
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Talk n Characteristics of the patients
Total number of patients
Age
Median
Range
Gender (male-female)
Karnofsky
Median
Range
Preous chemotherapy
Previous MDR-related drugs
Median number of MDR-related drugs
Range
Tumour type
Breast carcinoma
Soft tissue sarcoma
Ewing's sarcoma
Non-small-cell lung carcinoma
Others
18
48
20-63
7:11
70
50-90
18
17
2
0-4
5
5
2
2
4
Toxicity
A total of 39 cycles were administered to the 18 patients
(Table I). The median number of treatment cycles per patient
was two, range 1-6. All treatment cycles were evaluated for
toxicity. Reasons for withdrawal from treatment in the eight
patients who received a single course of therapy were PD
(six) and refusal of further therapy in presenc of SD (two).
Haematological toxicty was greater than expected for the
same chemotherapy alone. Out of 39 cycles inistered, 18
(46%) presented leucopenia grades Ill and IV, and nine
(23%) had thrombopenia grades Ill and IV (Table HII).
Eleven out of 18 patients (61%) experienced leuco- or throm-
bopenia grades III and IV. One patient died of intracanial
haemorrhage due to severe thrombopenia. Infectious episodes
occurred in two patients. Of ten patients who received more
than one treatment cycle, DOX and IFX were reduced in
four (40%) owing to severe leucopenia and/or thrombopenia.
Vomiting grades H and III occurred in 30 cycles but were
well controlled with antiemetics and ceased rpily after
finishing the treatment cycls. Grade H mucositis occurred in
five cycles and grade III in one. Four patients (22%)
experienced this toxicity. Nephrotoxicity developed in eight
cycles (20%), and consisted only of mild and reversible inc-
reases in blood creatinine. All patients who experienced this
toxicity were treated at CsA c.i. doses of 14 mg kg-' day-' or
greater. None of the patients presented severe nephrotoxicity.
Mild and reversible hypomagemia was seen in 28 out of
39 cycles (72%), but was well controlled with intravenous
magnesium supplements. All patients experienced>5% and
< 10% increase in body weight during therapy due to fluid
retention, which responded well to diuretics.
Reversible and asymptomatic hypeilirubinaemia without
alterations in hepatic enzymes, appeared in 18 out of 39
cycles (46%). The increase in total bilimbin was generally
detected within the first 24 h of CsA infusion and was related
to the dose of CsA (Table IV). Both direct and indirec
bilirubin levels were increased, but direct bi}irubin pre-
dominated. Hyperbirubinaeia was rapidly reversble at the
end of the treatment cycle, having lasted only 1 or 2 days.
Mid reversble arterial hypertenon was seen in six cycles
(15%). The maximum registered systolic pressure was 170,
the diastolic 100 muHg. Anti-hypertensive medication was
not required. Hda occurred in six cycles (15%) and was
well controlled with non-opioid analgesics. In two patients
with a less satisfactory control oral propranolol was success-
fully ministered. This symptom was reversible after
finishing treatment. Four patients presented pain in their
peviously cknown metastatic sites following the CsA lading
dose, and sometimes required opioid analgesics to control it.
Pain ceased soon after ending the cycle. There was no rea-
tionship between tumour response and appearance of pain in
Tae m Haematoogcal toxicity (number of cyles)a
WHO toxicity grades
Lewucocytes Platekts
Dose level III IV III IV
lOmgkg-' day-' 1 1 1
12mgkg'day' - 1 - 1
14mglkg'day- 4 3 - 3
16mglkg'day' 4 4 1 2
18 mg kg-' day-' 1 - - -
aTotal number of cycles was 39.
Table IV Hyperbirubinaemia and CsA dose klvel (number of
cyces)
WHO toxicity grades
Dose lvel I II III IV
10 mg kg-' day-' - 2
12 mg kg' day-' 2 - -
14mgkg-' day-' 5 3 1
16mglkg'day' 2 - -
18 mg kg-' day-' 1 - 4 1
Table V CsA pharnacokinetics
CsA dose level (mg kg-' day')
10 12 14 16 18
Cycles 3 9 15 8 4
assesscd
Steady state 941.46 1588 1813 2162 2293
(ng ml-') ± 68.7 ± 292 ± 507 ± 467 ± 807
metastases. Only one of these four patients experieced
symptomatic miprovement Anaphylactic reactions were not
seen, although facial flushing occasionally occurred. No
relevant neurological toxicity was observed. One patient with
metastatic soft tissue sarcoma developed congestive cardiac
failure grade H of the New York Heart Association (NYHA)
after receiving a total cmulative DOX dose of 555 mg m-2.
CsA pharmacokinetics
After the CsA loading dose (5 mg kg-') mean whole blood
concentration was 2652 ng ml In Table V the mean steady-
state CsA concentration values are shown. CsA blood levels
showed a high interpatient variability. Whole blood levels of
1200 ng ml-' or greater were obtained at the second or
higher dose level. Mean steady-state concentrations of
2000 ng ml-' were achieved at the fourth dose level
(16mg kg-l day-' CsA c.i.). Three more patients who
received four treatment cycles were included in a fifth dose
level at 18 mg kg-' day-'. The mean steady-state CsA con-
centration at this level was 2293 ngml'. Patient 10, a 44-
year-old woman with breast cancer treated at the third dose
level (14mg kg' day-' CsA c.i.), achieved CsA concentra-
tion of 1020 ng ml-' which was confirmed by repetition. This
individual's low levwl as compared with her escalation group
(see Table V) might be assocated with her being treated
chronially with phenobarbital to avoid seizums. This patient
(the single one with brain metastases in our study) presented
two small, well crcumscribed and asymptomatic brain metas-
tases as evidenced by MRI. After her first cycle she was
treated at a higher dose level of 16mg kg-'day-' CsA c.i.
owing to the improvement of her peripheral disease (skin
metastases), in order to see whether a higher CsA level could
improve her brain lesions as well. Patient 16, a 21-year-old
female with Ewing's sarcoma, who had received a single
treatment course at 18 mg kg- day' CsA c.i., achieved a
CsA blood concentration of 1291 ng ml-', which was in the
range of concentrations obtained with the second dose level
(see Table V). The age of this patient may have contributed
to the low CsA level obtained. Prior studies have shown that
1296
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young adults maN need higher doses to achieve a targeted
CsA level (Yee et al.. 1986: Kahan and Grevel. 1988).
Maximum tolerated dose and dose recommendations
The MTD as defined in this study. was not reached. Dose
escalations occurred from 10 to 18 mg kg' day' CsA c.i.
The single grade III toxicity observed. mucositis (excluding
myelosuppression and nausea and vomiting), was seen in one
patient treated at the third dose level. No other patient at
this dose level experienced grade III or IV toxicity and
further dose escalation continued. Hyperbilirubinaemia was
not considered a dose-limiting toxicity since it was reversible.
and no simultaneous alterations of liver enzymes were
detected.
The objective of this study. to obtain a CsA plasma con-
centration of 2000 ng ml' was achieved at the highest CsA
doses. A loading i.v. CsA dose of 5 mg kg-' followed by a 3
day CsA c.i. at doses of 16 or 18mgkg-'day-', lead to a
mean steady-state CsA concentration of 2000 ng ml-' or
greater. At such levels toxicity is tolerable and reversible.
T cellfunction studies (Figure 1I
Companrng the different lymphocyte subpopulations seen
before and 12 h after every cycle in 14 patients, there were
significant decreases in the total lymphocyte counts (P=
0.0002). and in CDl9 (P = 0.0007), CD3 (P = 0.00018). CI4
(P= 0.0164) and CD8 (P= 0.0003) subpopulations. In seven
patients who received more than one cycle, basal pretherapy
counts were compared in the first and last treatments, with
no significant differences in total lymphocyte counts
(P=0.8). nor in CD19 (P=0.7). CD3 (P=0.8), CD4
(P= 0.3) and CD8 (P= 0.8) subpopulations. Similarly a
significant increase in the CD4 CD8 lymphocyte ratio was
detected in 14 patients (P = 0.02). but again no differences
were observed between the first and the last cycle of therapy
in seven patients with more than one cycle (P = 1.0). In 12
patients. PHA LTI showed no significant differences between
basal and post-treatment values (P = 0.75). In five patients
who received more than one cycle. the value of basal LTI
before the first cvcle was similar to the value obtained before
the last cycle (P = 0.50).
Responses
There were two objective remissions (11%)o95% confidence
intervals 1.38-34.71%). One patient (treated with CsA c.i. at
16 mg kg-' day-) with an epidermoid carcinoma of the cer-
vix with pulmonary and bone metastases, had a PR lasting
2.5 months and another patient (treated with CsA c.i. at
14 mg kg-' day-') with metastatic Ewing's sarcoma, had a
PR lasting 8 months.
Curiously. two patients (one with breast cancer and
another with soft tissue sarcoma) who experienced PD
showed a decrease of more than 50% in the size of isolated
metastatic lesions with simultaneous increase of other lesions.
Finally, another patient (treated with CsA c.i. at
14 mg kg-' day-') with metastatic breast cancer showed
symptomatic pain relief and improvement in performance
status without objective response in measurable tumour for 6
months.
Disuson
Preliminary studies (Rodenburg et al.. 1991; Verweij et al.,
1991) using CsA as a modifier of drug resistance in combina-
tion with MDR cytotoxins in colon and renal carcinomas.
showed that CsA levels of 1000-2000 ng ml-' could be
achieved in the clinic with acceptable toxicity, although no
activity was observed using this approach in such tumour
types. These tumours are also resistant to many anti-cancer
drugs which are not MDR related, including ifosfamide.
Owing to the negative results of these trials and the intrinsic
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chemoresistance showed by such tumours. we decided to
exclude tumours that constitutively express P-gp. In order to
explore whether the modulating properties of CsA in vitro are
of clinical relevance in resistant solid tumours. we undertook
a phase I pilot study with intermittent high doses c.i. of CsA
plus DOX and IFX. Besides its anti-tumoural effect. IFX was
added because it causes glutathione depletion in vitro and in
vivo. and may reverse DOX resistance. In fact. 72% of our
patients were clinically resistant to DOX and an additional
11% to DHAD. In addition. 58% of the patients had failed
to respond to prior combination chemotherapy that con-
tained IFX.
The major aim of this study was to establish the dose of
CsA needed to achieve a steady-state concentration of
2000 ng ml-' and the toxicity associated with this dose.
Although we observed a great interpatient vanability in the
steady-state levels achieved, this study shows that a concen-
tration of 2000 ng ml-' can be achieved with a CsA loading
dose of 5 mg kg-' followed by a 3 day c.i. at doses>
14 mg kg-' day-' with acceptable toxicity.
Analysis of DOX pharmacokinetics was not an objective
of our clinically oriented pilot study. since this question has
been analysed by others. who found that a pharmacokinetic
interaction between high doses of CsA and DOX really does
exist (Sonneveld et al.. 1992; Bartlett et al.. 1993: Erlichman
et al.. 1993). Although our results do not allow conclusions
on possible pharmacological interactions, we have observed
an increased myelosuppression with our protocol. We corr-
elated our results with those of Millward et al. (1990). who
used the same drugs at a similar planned dose intensity
without CsA. but obtained a lesser haematological toxicity.
Further evidence for greater haematological toxicity comes
from our previous experience with similar doses of DOX and
IFX in the treatment of metastatic soft tissue sarcomas
(Gonzalez-Manzano et al., 1993). It is interesting to note the
distribution of the haematological toxicity in our study. Most
of the cycles (18 39 leucopenia and 9 39 thrombopenia) in
which haematological toxicity was present, resulted in grade
III or IV toxicity. and only one presented grade II
leucopenia. This difference may be related to the phar-
macokinetics of CsA. as shown by the high inter-patient
variability observed in the steady-state CsA levels achieved.
Chronic treatments with CsA alone in patients receiving
organ transplantation usually induce modifications in T-cell
subsets. such as a decrease in the number of CD4 cells and.
to a lesser extent. in the CD8 cells, with a concomitant
decrease in the CD4 CD8 ratio (Awni. 1992). In such situa-
tions, CsA also decreases the LTI (Awni. 1992). Prior studies
using intermittent high doses of CsA as a modifier of drug
resistance in combination with chemotherapy. have suggested
that a significant immunosuppression in patients receiving
such treatments does not occur. but so far this has not been
substantiated analytically. To our knowledge our present
study is the first detailed report analysing the changes of
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several lymphocyte subsets and the LTI associated with inter-
mittent high doses of CsA and chemotherapy. We have
shown that short-term variations (a signifint decrease in the
CD3, CD4, CD8 and CDl9 subpopulation counts) really
occur early after treatment, and that these changes are rever-
sible. This is shown in the patients who received more than
one treatment cycle and yet did not show a signnt
decrease in the lymphocyte subpopulations studied. The LTI
was not significantly modified by this treatment, either early
after treatment or later. In addition, no opportunisc infec-
tions were observed. Taken together these results appear to
suggest that this treatment can be safely inistered with-
out inducing a significant immunosuppressive status.
In contrast with the tendency of CsA and different
schedules of combination chemotherapy to reduce the
number of CD4 cells to a greater extent than CD8 cells,
resulting in a decrease of the CD4/CD8 ratio (Olsen et al.,
1988; Favrot et al., 1983; Linch et al., 1983; Onsrud et al.,
1986), we have documented a signifint increase of the
CD4/CD8 ratio early after treatment with this protocol. We
do not know whether such smalkr CD4 decreases in com-
parison with CD8 cells occurring early after treatment may
be considered a result of an effective modulation of the P-gp
expressed by these lymphocyte subpopulations. Recent
studies have evaluated the expression and activity of P-gp in
human subpopulations of normal peripheral blood and bone
marrow cells (Chaudhary et al., 1992; Drach et al., 1992). A
functional P-gp was found to be expressed in all peripheral
blood subpopulations (CD4, CD8, CD14, CD19, CD56)
except granulocytes. In the study of Chaudhary et al. (1992),
P-gp was expressed in the majority of the CD8, CD56 and
CD20 peripheral blood cells (60-90%), but only in kss than
one-half of CD4 cells. Although an effective modulation of
DOX by high doses of CsA explains our observations regar-
ding the increase in the CD4/CD8 ratio, alternative explana-
tions may be greater CD8 cell sensitivity to chemotherapy
(than CD4 cells) and/or that CD8 cells have shorter survival
times. The toxicities observed with our protocol were similar
to those reported m other phase I trals with intemttent
high doses of CsA given as modifier of drug resistance
(Yahanda et al., 1992; Erlichman et al., 1993; List et al.,
1993). Such toxicities were: hyperbiirubinm (46% cycles),
hypomagnesaemia (72% of cycles), hypertension (15%),
nephrotoxicity (20%) and mild to moderate fluid retention
(100%). Hypomagnesaemia was easily manaeable and no
clinical symptomatology was seen. Nephrotoxicity was mild
and reversible in five patients. Three of them had received
prior treatment with cisplatin, and a possible predisposition
to experience nephrotoxicity in these patients cannot be dis-
carded. Neverthelss, we have observed a similar incidence of
this toxicty as compared with other recently pubished series
(Yahanda et al., 1992; Edichman et al., 1993), and no
episodes of acute renal failure have been observed. Two
patients obtained a PR with our protocol. Interestingly, one
of them was a patient with Ewing's sarcoma who was pro-
gressing after treatment with the same drugs without CsA.
The addition of CsA to the same agents that faied
previously induced a PR. This patient presented acquired
istance to prior DOX-based chemotherapy.
It remains to be elaborated whether adequate levels of CsA
reached the tumour cells, in our study as well as past studies.
The inaccessability of metastatic lesions in most of our cases
precluded tumour biopsy for determination of CsA. At pres-
ent, it is not known whether adequate plasma levels of CsA
are associated with good intratumour levels. It would be
convenient to address such question in the design of future
studies with CsA, although feasibility may constitute a
significnt problem in solid tumours.
In summary, CsA steady-state levels of 2000 ng ml-I can
be achieved with a loading dose of 5 mg kg-1 followed by a 3
day CsA c.i. at a dose of 16mgkg-' day-' in combination
with DOX and IFX, with accptable toxicity. Although some
encouraging resonses have been observed, and an attempt
to modulate resistance by different mechanisms appears inter-
esting, further evaluation is needed to establish the clinical
value of this approach in seected tumour types.
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